21 September 2021 - The institute and the G-BA are part of a consortium that is developing the methodological basis ...
16 September 2021 - Do patients with COVID-19 have a better chance of surviving and recovering faster if they are treated ...
16 September 2021 - For nivolumab (Opdivo), the pharmaceutical company was able to achieve a significantly better result in a second ...
15 September 2021 - Third new area of application/those affected still live a good year on average - and thus ...
23 August 2021 - The IQWiG has presented the draft for the next version of its General Methods. ...
16 August 2021 - With risdiplam there is a hint of an added benefit for spinal muscular atrophy type 1, ...
16 August 2021 - The active ingredient has exceeded the sales limit for the simplified orphan drug assessment. There are no ...
5 August 2021 - The Federal Joint Committee (G-BA) today evaluated the new cancer drug with the trade name Tecartus and ...
15 July 2021 - The Federal Joint Committee (G-BA) today certified two active ingredients with a "considerable additional benefit". It assigns ...
1 July 2021 - COVID-19 patients with pneumonia who do not yet require high-flow oxygen therapy benefit from remdesivir: they recover ...
29 May 2021 - Three years after the original proposal, the European Union’s game changing Health Technology Assessment dossier has ...
27 April 2021 - The European Network for Health Technology Assessment (EUnetHTA) was established in 2006 and comprises over eighty organisations ...
22 April 2021 - When Bluebird Bio secured European approval for its gene therapy to treat beta thalassaemia in 2019, ...
19 March 2021 - IQWiG evaluated a total of 24 manufacturer dossiers punctually for the dates March 1 and March 15. ...
1 March 2021 - The treatment delays permanent ventilation of the children and extends life. In addition, the children develop more ...